A growing number of small biopharma companies are launching drugs independently and trying to build commercial traction. Successful commercial execution is not an easy feat for small companies, which generally have less to spend on commercial infrastructure and fewer resources to tap into.
Key Takeaways
- Several small biopharma companies are launching drugs independently and trying to build commercial traction, not always an easy feat.
In some cases, these solo launches also represent the company’s first commercial product. Scrip took a look at how some...
